Radius common stock is traded on the NASDAQ Global Market under the ticker symbol "RDUS."

750469 207

950 Winter St
Waltham, MA 02451

Radius does not offer a direct stock purchase plan. Shares of the Company should be purchased through a broker.

Radius does not currently pay a dividend.

Wells Fargo Shareowner Services
1110 Centre Pointe Curve
Ste. 101
Mendota Heights, MN 55120-4100
(800) 468-9716

To replace lost certificates, contact the transfer agent at:

Wells Fargo Shareowner Services
1110 Centre Pointe Curve
Ste. 101
Mendota Heights, MN 55120-4100
(800) 468-9716

To notify of a change in address, contact the transfer agent at:

Wells Fargo Shareowner Services
1110 Centre Pointe Curve
Ste. 101
Mendota Heights, MN 55120-4100
(800) 468-9716

Radius’ fiscal year is based on the calendar year.

First Quarter ends 3/31, Second Quarter ends 6/30, Third Quarter ends 9/30 and Fourth Quarter ends 12/31.

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases.

Radius' lead product, TYMLOS (abaloparatide) Injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical pipeline includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius' RAD140, a non-steroidal, selective androgen receptor modulator (SARM), is under investigation for potential use in hormone receptor positive breast cancer.

Please submit your question using the form below.

Contact Form
* Indicates required field
http://apps.shareholder.com/captcha/captcha.aspx?verifyid=1938749230&CompanyID=AMDA-1D3H6P&t=.jpg